Search results
Results from the WOW.Com Content Network
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [1] [2] It is used together with a diabetic diet and exercise. [1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth.
A convergence between phenotypic and metabolic state transitions that confers a survival advantage to cancer cells against clinically used drug combinations like taxanes and anthracyclines have also been reported while drug resistant cancer cells had increased activity of both the glycolytic and oxidative pathways and glucose flux through the ...
Otto Warburg postulated this change in metabolism is the fundamental cause of cancer, [8] a claim now known as the Warburg hypothesis. Today, mutations in oncogenes and tumor suppressor genes are thought to be responsible for malignant transformation , and the Warburg effect is considered to be a result of these mutations rather than a cause.
GLP-1 agonists are being studied for the treatment of non-alcoholic fatty liver disease (NAFLD). They are at least as effective as the medications in current use, pioglitazone and Vitamin E , and significantly reduce steatosis, ballooning necrosis, lobular inflammation, and fibrosis according to a 2023 systematic review. [ 18 ]
In cancer, there are several reprogrammed metabolic pathways that help cells survive when nutrients are scarce: Aerobic glycolysis, an increase in glycolytic flux, also known as the Warburg effect, allows glycolytic intermediates to supply subsidiary pathways to meet the metabolic demands of proliferating tumorigenic cells. [10]
Insulins are typically characterized by the rate at which they are metabolized by the body, yielding different peak times and durations of action. [4] Faster-acting insulins peak quickly and are subsequently metabolized, while longer-acting insulins tend to have extended peak times and remain active in the body for more significant periods. [5]
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. [25]
Patients in response categories 4-9 should be considered as failing to respond to treatment (disease progression). Thus, an incorrect treatment schedule or drug administration does not result in exclusion from the analysis of the response rate. Precise definitions for categories 4-9 will be protocol specific.